NeurologyAbbVie
AbbVie Reports Phase 3 PROGRESS Trial Results for Qulipta in Chronic Migraine Prevention
BMI
Biotechnology Media Insights
Editorial Team · August 22, 2025
AbbVie announces Phase 3 PROGRESS trial results showing atogepant (Qulipta) significantly reduces monthly migraine days in adults with chronic migraine.
AbbVie today announced results from the Phase 3 PROGRESS trial evaluating Qulipta (atogepant) for the preventive treatment of chronic migraine in adults. The trial met its primary endpoint, demonstrating a significant reduction in mean monthly migraine days compared to placebo at weeks 1-12.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.